Ligand Pharmaceuticals – pharmaceutical daily

May 6, 2020 Off

Ligand’s net loss in Q1 2020 went to $24.1 million from profit of $666.3 million in Q1 2019

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the first quarter with strong sales of Captisol to partners evaluating remdesivir in multiple clinical trials and scaling-up for potential treatment courses for COVID-19

July 2, 2019 Off

ZULRESSO Launched by Sage Therapeutics, 11th FDA-approved drug to use Ligand’s Captisol technology

By BusinessWire

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that Sage Therapeutics has launched ZULRESSO™ (brexanolone) injection, which was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019, and is the first and only treatment specifically approved for postpartum depression (PPD), one of the most common medical complications during and after pregnancy.

March 21, 2019 Off

Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection

By BusinessWire

ZULRESSO is the first and only treatment specifically indicated for postpartum depression SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced…